Literature DB >> 10984496

Energetic and functional contribution of residues in the core binding factor beta (CBFbeta ) subunit to heterodimerization with CBFalpha.

Y Y Tang1, J Shi, L Zhang, A Davis, J Bravo, A J Warren, N A Speck, J H Bushweller.   

Abstract

Core-binding factors (CBFs) are a small family of heterodimeric transcription factors that play critical roles in several developmental pathways, including hematopoiesis and bone development. Mutations in CBF genes are found in leukemias and bone disorders. CBFs consist of a DNA-binding CBFalpha subunit (Runx1, Runx2, or Runx3) and a non-DNA-binding CBFbeta subunit. CBFalpha binds DNA in a sequence-specific manner, whereas CBFbeta enhances DNA binding by CBFalpha. Recent structural analyses of the DNA-binding Runt domain of CBFalpha and the CBFbeta subunit identified the heterodimerization surfaces on each subunit. Here we identify amino acids in CBFbeta that mediate binding to CBFalpha. We determine the energy contributed by each of these amino acids to heterodimerization and the importance of these residues for in vivo function. These data refine the structural analyses and further support the hypothesis that CBFbeta enhances DNA binding by inducing a conformational change in the Runt domain.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10984496     DOI: 10.1074/jbc.M007350200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  28 in total

1.  RUNX1 repression-independent mechanisms of leukemogenesis by fusion genes CBFB-MYH11 and AML1-ETO (RUNX1-RUNX1T1).

Authors:  R Katherine Hyde; P Paul Liu
Journal:  J Cell Biochem       Date:  2010-08-01       Impact factor: 4.429

2.  A structure-based benchmark for protein-protein binding affinity.

Authors:  Panagiotis L Kastritis; Iain H Moal; Howook Hwang; Zhiping Weng; Paul A Bates; Alexandre M J J Bonvin; Joël Janin
Journal:  Protein Sci       Date:  2011-02-16       Impact factor: 6.725

3.  Downregulation of RUNX1/CBFβ by MLL fusion proteins enhances hematopoietic stem cell self-renewal.

Authors:  Xinghui Zhao; Aili Chen; Xiaomei Yan; Yue Zhang; Fuhong He; Yoshihiro Hayashi; Yunzhu Dong; Yalan Rao; Bo Li; Rajeana M Conway; Alba Maiques-Diaz; Shannon E Elf; Nuomin Huang; Johannes Zuber; Zhijian Xiao; William Tse; Daniel G Tenen; Qianfei Wang; Wei Chen; James C Mulloy; Stephen D Nimer; Gang Huang
Journal:  Blood       Date:  2014-01-21       Impact factor: 22.113

4.  A mutation in the S-switch region of the Runt domain alters the dynamics of an allosteric network responsible for CBFbeta regulation.

Authors:  Zhe Li; Steven M Lukasik; Yizhou Liu; Jolanta Grembecka; Izabela Bielnicka; John H Bushweller; Nancy A Speck
Journal:  J Mol Biol       Date:  2006-10-04       Impact factor: 5.469

5.  HDAC1 Is a Required Cofactor of CBFβ-SMMHC and a Potential Therapeutic Target in Inversion 16 Acute Myeloid Leukemia.

Authors:  Lisa E Richter; Yiqian Wang; Michelle E Becker; Rachel A Coburn; Jacob T Williams; Catalina Amador; R Katherine Hyde
Journal:  Mol Cancer Res       Date:  2019-02-27       Impact factor: 5.852

6.  Small molecule inhibition of the CBFβ/RUNX interaction decreases ovarian cancer growth and migration through alterations in genes related to epithelial-to-mesenchymal transition.

Authors:  Anne L Carlton; Anuradha Illendula; Yan Gao; Danielle C Llaneza; Adam Boulton; Anant Shah; Roger A Rajewski; Charles N Landen; David Wotton; John H Bushweller
Journal:  Gynecol Oncol       Date:  2018-03-16       Impact factor: 5.482

7.  Cbfb/Runx1 repression-independent blockage of differentiation and accumulation of Csf2rb-expressing cells by Cbfb-MYH11.

Authors:  R Katherine Hyde; Yasuhiko Kamikubo; Stacie Anderson; Martha Kirby; Lemlem Alemu; Ling Zhao; P Paul Liu
Journal:  Blood       Date:  2009-12-09       Impact factor: 22.113

8.  RUNX2 mutations in Chinese patients with cleidocranial dysplasia.

Authors:  Yalin Li; Wei Pan; Wanfeng Xu; Nan He; Xuewu Chen; Hong Liu; L Darryl Quarles; Honghao Zhou; Zhousheng Xiao
Journal:  Mutagenesis       Date:  2009-06-10       Impact factor: 3.000

9.  CBFβ stabilizes HIV Vif to counteract APOBEC3 at the expense of RUNX1 target gene expression.

Authors:  Dong Young Kim; Eunju Kwon; Paul D Hartley; David C Crosby; Sumanjit Mann; Nevan J Krogan; John D Gross
Journal:  Mol Cell       Date:  2013-01-17       Impact factor: 17.970

10.  Identification of benzodiazepine Ro5-3335 as an inhibitor of CBF leukemia through quantitative high throughput screen against RUNX1-CBFβ interaction.

Authors:  Lea Cunningham; Steven Finckbeiner; R Katherine Hyde; Noel Southall; Juan Marugan; Venkat R K Yedavalli; Seameen Jean Dehdashti; William C Reinhold; Lemlem Alemu; Ling Zhao; Jing-Ruey Joanna Yeh; Raman Sood; Yves Pommier; Christopher P Austin; Kuan-Teh Jeang; Wei Zheng; Paul Liu
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-21       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.